Pharmaceutical Crystals
The crystalline state is the most commonly used essential solid active pharmaceutical ingredient (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines, but the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutic...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Book Chapter |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04155naaaa2200913uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_56130 | ||
| 005 | 20210211 | ||
| 020 | |a books978-3-03928-713-0 | ||
| 020 | |a 9783039287123 | ||
| 020 | |a 9783039287130 | ||
| 024 | 7 | |a 10.3390/books978-3-03928-713-0 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 100 | 1 | |a Uekusa, Hidehiro |4 auth | |
| 700 | 1 | |a Yonemochi, Etsuo |4 auth | |
| 245 | 1 | 0 | |a Pharmaceutical Crystals |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (148 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The crystalline state is the most commonly used essential solid active pharmaceutical ingredient (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines, but the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. This book entitled "Pharmaceutical Crystals"" focuses on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts, and hydrates, and polymorph crystals are reported. Such crystal structures were investigated in the latest studies that combined morphology, spectroscopic, theoretical calculation, and thermal analysis with crystallographic study. This book highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure-property study of pharmaceutical crystals. The Guest Editors of this book hope the readers enjoy a wide variety of recent studies on Pharmaceutical Crystals. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a crystal structure analysis | ||
| 653 | |a n/a | ||
| 653 | |a famotidine | ||
| 653 | |a solution crystallization | ||
| 653 | |a salt optimization | ||
| 653 | |a structure determination from powder diffraction data | ||
| 653 | |a Hirshfeld surface analysis | ||
| 653 | |a DFT | ||
| 653 | |a molecular docking study | ||
| 653 | |a melting diagram | ||
| 653 | |a dehydration | ||
| 653 | |a hygroscopicity | ||
| 653 | |a HBV | ||
| 653 | |a Benzodioxole | ||
| 653 | |a pharmaceutical crystals | ||
| 653 | |a 4-b]indol-4-one | ||
| 653 | |a pyrimidin-4(3H)-one | ||
| 653 | |a liquid assisted grinding | ||
| 653 | |a HOMO-LUMO | ||
| 653 | |a dissolution | ||
| 653 | |a cocrystal formation | ||
| 653 | |a Raman spectroscopy | ||
| 653 | |a carbamazepine | ||
| 653 | |a hydrogen bonding | ||
| 653 | |a 3 | ||
| 653 | |a ondansetron | ||
| 653 | |a physicochemical properties | ||
| 653 | |a solubility | ||
| 653 | |a succinic acid | ||
| 653 | |a cocrystal | ||
| 653 | |a adefovir dipivoxil | ||
| 653 | |a hepatitis B | ||
| 653 | |a polymorphs | ||
| 653 | |a hydrogen-bond-acceptance ability | ||
| 653 | |a DFT study | ||
| 653 | |a Nitrofurantoin-4-dimethylaminopyridine (NF-DMAP) salt | ||
| 653 | |a photostability | ||
| 653 | |a on-line monitoring | ||
| 653 | |a 5-dihydro-4H-pyrimido[5 | ||
| 653 | |a Imidazole | ||
| 653 | |a Semicarbazone | ||
| 653 | |a crystal habit | ||
| 653 | |a Crystal structure | ||
| 653 | |a solvent-mediated polymorphic transformation | ||
| 653 | |a ticagrelor | ||
| 653 | |a hydrate | ||
| 653 | |a pharmaceutical cocrystal | ||
| 653 | |a malonic acid | ||
| 653 | |a 1H-indole | ||
| 653 | |a reactivity descriptors | ||
| 653 | |a famoxadone | ||
| 653 | |a crystal structure | ||
| 653 | |a dicarboxylic acid | ||
| 653 | |a hydrogen bond | ||
| 653 | |a saccharin | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2162 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/56130 |7 0 |z DOAB: description of the publication |